Clinical trials: Chronic Obstructive Pulmonary Disease Severe
COPD, COPD Bronchitis
NBMI - Clinical Study on COPD
A pilot study to explore safety of the treatment with the antioxidant and metal chelator NBMI in COPD patients. Investigational product: NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide), INN: Emeramide Indication: Mild, moderate…
- Trial name
- Emera003COPD (NCT03123692)
- Testing
- Emeramide
- Volunteers
- 12 people
- Sponsor
- EmeraMed
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients
The main purpose of this study is to assess the long term bronchodilator efficacy, safety and tolerability of inhaled aclidinium bromide at two dose levels compared to placebo in COPD patients and the benefits of the product in…
- Trial name
- NCT01001494
- Testing
- Aclidinium bromide 200 μg bid, Aclidinium bromide 400 μg bid
- Where
- 106 sites in Czechia, France and 9 more
- Volunteers
- 828 people
- Sponsor
- AstraZeneca
Pulmonary Emphysema
Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema
Actively developing stem cells (SCs) transplantation techniques cause natural interest to the problem of regeneration in the lungs.
- Trial name
- NCT01849159
- Testing
- Mesenchymal stem cells, Reference therapy: 400 mL of 0.9% NaCl solution
- Where
- Russia
- Sponsor
- Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease…
- Trial name
- INTRUST2 (NCT00877383)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 176 sites in United States, Canada and 7 more
- Volunteers
- 1,142 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
This is a randomised, controlled, two period cross-over, 4 weeks chronic dosing, study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) and Glycopyrronium/Formoterol Fumarate (GFF) on airway…
- Trial name
- NCT03836677
- Testing
- BGF, GFF
- Where
- 4 sites in Belgium, Netherlands
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
COPD Method Evaluation, Chronic Obstructive Pulmonary Disease Method Evaluation
Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler
The main purpose of this study is to evaluate the sensitivity of a new oxygen enhanced magnetic resonance imaging (OE-MRI) method in detecting changes in the lungs of patients with moderate to severe chronic obstructive pulmonary…
- Trial name
- NCT01257048
- Testing
- Formoterol Turbuhaler, Budesonide/Formoterol Turbuhaler
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the onset of action of indacaterol (150 and 300 µg) as compared to placebo, salbutamol 200 µg and salmeterol/fluticasone 50/500 µg
- Trial name
- NCT00669617
- Testing
- Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg)
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 89 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Diseases, COPD
Effect of IMT in Patients After Acute Exacerbations of COPD
The goal of this clinical trial is to test whether home-based inspiratory muscle training can reduce hospital readmissions and death in patients recovering from a severe acute exacerbation of chronic obstructive pulmonary disease…
- Conditions
- Chronic Obstructive Pulmonary Diseases, COPD, Symptom Exacerbation
- Trial name
- IN-SPIRED (NCT07213128)
- Testing
- Training
- Where
- 12 sites in Belgium
- Volunteers
- 358 people
- Sponsor
- KU Leuven
Pulmonary Disease, Chronic Obstructive
Severe Chronic Obstructive Pulmonary Disease Inhalation Profiles Comparison
This purpose of this study is to obtain inhalation profiles in subjects with very severe Chronic Obstructive Pulmonary Disease (COPD). This is a study with no investigational medicinal product.
- Trial name
- NCT02076269
- Testing
- No Intervention
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine whether there is a statistical association between changes in sputum serial levels of two cytokines, interleukin (IL)-17 and IL-6, during the treatment course of a severe acute…
- Trial name
- NCT00281242
- Testing
- blood draw
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Michigan
Chronic Obstructive Pulmonary Disease (COPD), Severe Asthma
COINCIDE: Cardineurovascular dIsease and Obstructive Airway Disease
Patients with chronic obstructive pulmonary disease (COPD) and severe asthma frequently present with cardiovascular comorbidities that contribute substantially to morbidity and mortality.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Severe Asthma, Cardiovascular Diseases
- Trial name
- COINCIDE (NCT07856667)
- Testing
- Routine Clinical Care
- Volunteers
- 350 people
- Sponsor
- VASCage GmbH
Emphysema
A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema
This is a multicenter,single-arm,open-label study designed to evaluate improvement of lung function and safety after treatment with OL-BF-001 for severe emphysema.
- Trial name
- NCT02470052
- Testing
- OL-BF-001
- Where
- 10 sites in Japan
- Volunteers
- 38 people
- Sponsor
- Olympus Corporation
Chronic Obstructive Pulmonary Disease Severe, Muscle Weakness
Additional Manual Therapy Over Inspiratory Muscle Training in COPD
The benefits of inspiratory muscle training(IMT) in patients with chronic obstructive pulmonary disease(COPD) were reported.But in severe COPD patients, benefit from IMT may be limited.There is need for further research in new…
- Trial name
- NCT04533516
- Testing
- Manual therapy technics, Inspiratory Muscle Training
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Istinye University
COPD (Chronic Obstructive Pulmonary Disease)
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD).
- Trial name
- Sirius (NCT07646587)
- Testing
- WIN378
- Where
- 32 sites in United States, Argentina
- Volunteers
- 105 people
- Sponsor
- Windward Bio
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies
- Trial name
- GALATHEA (NCT02138916)
- Testing
- Benralizumab Arm A, Benralizumab Arm B
- Where
- 407 sites in United States, Austria and 15 more
- Volunteers
- 1,656 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD), Whole Body Vibration
Acute Effect of Different Frequency of Whole Body Vibration (WBV) on Healthy and Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is an irreversible disorder characterized by persistent airflow limitation and increased lung compliance.
- Trial name
- NCT07509606
- Testing
- Whole body vibration
- Where
- Taiwan
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- National Cheng Kung University
COPD (Chronic Obstructive Pulmonary Disease), COPD
Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD
The purpose of this Phase IIa study is to evaluate the safety, efficacy, and pharmacokinetics of JKN2304 Inhalation Solution in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT07450482
- Testing
- JKN2304 Inhalation Solution, Formoterol Fumarate Inhalation Solution
- Where
- 8 sites in China
- Volunteers
- 42 people
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
COPD, Pulmonary Emphysema
ELVR in PH Patients With Severe Emphysema
The purpose of this study is to investigate the effect of endoscopic valve implantation in patients with COPD and PH on hemodynamics, symptoms, exercise tolerance and quality of life in 10 patients in a prospective study.
- Trial name
- NCT01393379
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Heidelberg University
COPD
Home Non-Invasive Ventilation Targeting Expiratory Flow Limitation in Severe Hypercapnic COPD.
In this 2-phase pilot study, the BiPAP A40 EFL will be evaluated in patients with severe COPD requiring home non-invasive ventilatory support with respect to patient-related and physiologic outcomes.
- Trial name
- NCT05109754
- Testing
- BiPAP EFL
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Chronic Obstructive Pulmonary Disease
A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the lung effects of indacaterol to those of tiotropium in patients with moderate to severe chronic obstructive pulmonary disease (COPD) over a 12 week period.
- Trial name
- INTENSITY (NCT00900731)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 212 sites in United States, Austria and 20 more
- Volunteers
- 1,598 people
- Sponsor
- Novartis Pharmaceuticals